BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lung cancer AND TRIM24, O15164, 8805, ENSG00000122779, TIF1ALPHA, TF1A, TIF1A, hTIF1, Tif1a, TIF1, RNF82, PTC6 AND Treatment
15 results:

  • 1. Clinical features of dermatomyositis patients with anti-tif1 antibodies: A case based comprehensive review.
    Kilinc OC; Ugurlu S
    Autoimmun Rev; 2023 Dec; 22(12):103464. PubMed ID: 37863375
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Immune checkpoint inhibitor therapy in a patient with small cell lung cancer and anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis: A case report.
    Kim Y; Park D; Choi SY; Chung C
    Thorac Cancer; 2022 Oct; 13(19):2808-2811. PubMed ID: 35982637
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Development of dermatomyositis after anti-transcriptional intermediary factor 1-γ antibody seroconversion during treatment for small cell lung cancer.
    Sato Y; Tanino Y; Nikaido T; Togawa R; Kawamata T; Watanabe N; Sato R; Yamada R; Onuma T; Tomita H; Saito M; Rikimaru M; Morimoto J; Suzuki Y; Minemura H; Saito J; Kanazawa K; Yamada S; Hashimoto Y; Shibata Y
    BMC Pulm Med; 2022 May; 22(1):191. PubMed ID: 35549684
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. [Dermatomyositis with squamous cell carcinoma of the lungs secondary to nivolumab treatment: a case report].
    Miyashita K; Kajikawa H; Utsunomiya T; Hosaka M; Naito Y; Tomimoto H
    Rinsho Shinkeigaku; 2020 Nov; 60(11):768-772. PubMed ID: 33115992
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Paraneoplastic Dermatomyositis in a Patient with Metastatic Gastric Carcinoma.
    Pozharashka J; Dourmishev L; Rusinova D; Balabanova M; Miteva L
    Acta Dermatovenerol Croat; 2020 Aug; 28(2):120-122. PubMed ID: 32876041
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Myositis-specific autoantibodies and their clinical associations in idiopathic inflammatory myopathies.
    Wong VT; So H; Lam TT; Yip RM
    Acta Neurol Scand; 2021 Feb; 143(2):131-139. PubMed ID: 32762037
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis induced by nivolumab for lung adenocarcinoma: A case report.
    Osaki M; Tachikawa R; Ohira J; Hara S; Tomii K
    Invest New Drugs; 2021 Feb; 39(1):251-255. PubMed ID: 32651759
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Clinical significance of serum levels of anti-transcriptional intermediary factor 1-γ antibody in patients with dermatomyositis.
    Ikeda N; Yamaguchi Y; Kanaoka M; Ototake Y; Akita A; Watanabe T; Aihara M
    J Dermatol; 2020 May; 47(5):490-496. PubMed ID: 32103537
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Current understanding and recent advances in myositis-specific and -associated autoantibodies detected in patients with dermatomyositis.
    Gono T; Kuwana M
    Expert Rev Clin Immunol; 2020 Jan; 16(1):79-89. PubMed ID: 31779485
    [No Abstract]    [Full Text] [Related]  

  • 10. trim24 as an independent prognostic biomarker for prostate cancer.
    Offermann A; Roth D; Hupe MC; Hohensteiner S; Becker F; Joerg V; Carlsson J; Kuempers C; Ribbat-Idel J; Tharun L; Sailer V; Kirfel J; Svensson M; Andren O; Lubczyk V; Kuefer R; Merseburger AS; Perner S
    Urol Oncol; 2019 Sep; 37(9):576.e1-576.e10. PubMed ID: 31178279
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Phosphorylation of TRIM28 Enhances the Expression of IFN-β and Proinflammatory Cytokines During HPAIV Infection of Human lung Epithelial Cells.
    Krischuns T; Günl F; Henschel L; Binder M; Willemsen J; Schloer S; Rescher U; Gerlt V; Zimmer G; Nordhoff C; Ludwig S; Brunotte L
    Front Immunol; 2018; 9():2229. PubMed ID: 30323812
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. The Latest in Surgical Management of Stage IIIA Non-Small Cell lung cancer: Video-Assisted Thoracic Surgery and Tumor Molecular Profiling.
    Woodard GA; Jablons DM
    Am Soc Clin Oncol Educ Book; 2015; ():e435-41. PubMed ID: 25993207
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Druggable oncogene fusions in invasive mucinous lung adenocarcinoma.
    Nakaoku T; Tsuta K; Ichikawa H; Shiraishi K; Sakamoto H; Enari M; Furuta K; Shimada Y; Ogiwara H; Watanabe S; Nokihara H; Yasuda K; Hiramoto M; Nammo T; Ishigame T; Schetter AJ; Okayama H; Harris CC; Kim YH; Mishima M; Yokota J; Yoshida T; Kohno T
    Clin Cancer Res; 2014 Jun; 20(12):3087-93. PubMed ID: 24727320
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805.
    Albain KS; Rusch VW; Crowley JJ; Rice TW; Turrisi AT; Weick JK; Lonchyna VA; Presant CA; McKenna RJ; Gandara DR
    J Clin Oncol; 1995 Aug; 13(8):1880-92. PubMed ID: 7636530
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Isolation of tumor cell growth-inhibiting factors from a human rhabdomyosarcoma cell line.
    Iwata KK; Fryling CM; Knott WB; Todaro GJ
    Cancer Res; 1985 Jun; 45(6):2689-94. PubMed ID: 3857121
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.